Media stories about Cantel Medical (NYSE:CMD) have trended positive on Saturday, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cantel Medical earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.21205408898 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Cantel Medical (NYSE:CMD) traded up $0.93 during mid-day trading on Friday, reaching $101.48. 115,660 shares of the company’s stock traded hands, compared to its average volume of 167,927. Cantel Medical has a 12-month low of $69.21 and a 12-month high of $108.00. The company has a market capitalization of $4,280.00, a price-to-earnings ratio of 56.07 and a beta of 1.24. The company has a current ratio of 2.44, a quick ratio of 1.48 and a debt-to-equity ratio of 0.31.
Cantel Medical (NYSE:CMD) last announced its quarterly earnings results on Thursday, September 28th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.02. Cantel Medical had a net margin of 9.50% and a return on equity of 17.42%. The company had revenue of $205.50 million during the quarter, compared to the consensus estimate of $200.32 million. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. equities research analysts predict that Cantel Medical will post 2.35 earnings per share for the current fiscal year.
Separately, Needham & Company LLC reiterated a “hold” rating on shares of Cantel Medical in a research note on Friday, September 1st. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $87.50.
In other Cantel Medical news, Chairman Charles M. Diker sold 20,500 shares of the company’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $99.15, for a total value of $2,032,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George L. Fotiades sold 6,000 shares of the company’s stock in a transaction dated Friday, October 13th. The shares were sold at an average price of $95.23, for a total transaction of $571,380.00. The disclosure for this sale can be found here. Insiders sold 36,368 shares of company stock valued at $3,576,028 in the last ninety days. Corporate insiders own 12.30% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Cantel Medical (CMD) Earning Favorable Press Coverage, Analysis Shows” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/12/23/cantel-medical-cmd-earning-favorable-press-coverage-analysis-shows.html.
About Cantel Medical
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
What are top analysts saying about Cantel Medical? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cantel Medical and related companies.